Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;23(3-b Suppl):S3-S4.
doi: 10.18553/jmcp.2017.23.3-b.s3.

Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension

Toby M Maher  1 , Fred Dejonckheere  2 , Steven D Nathan  3
Affiliations
Review

Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension

Toby M Maher et al. J Manag Care Spec Pharm. 2017 Mar.

Abstract

Maher has received grants, consulting fees, and speaker fees from GlaxoSmithKline and UCB and grants from Novartis. He has also received consulting fees and speaker fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Lanthio, InterMune International AG (a wholly owned Roche subsidiary since 2014), F. Hoffmann-La Roche, Sanofi-Aventis, and Takeda. Maher is supported by a National Institute for Health Research Clinician Scientist Fellowship (NIHR Ref: CS:-2013-13-017). Dejonckheere is an employee of F. Hoffmann-La Roche. Nathan has received consulting fees from Roche-Genentech and Boehringer Ingelheim. He is also on the speakers bureau for Roche-Genentech and Boehringer Ingelheim and has received research funding from both companies. All authors contributed equally to study concept and design, data collection and analysis, and manuscript preparation.

PubMed Disclaimer

Conflict of interest statement

Maher has received grants, consulting fees, and speaker fees from GlaxoSmithKline and UCB and grants from Novartis. He has also received consulting fees and speaker fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Lanthio, InterMune International AG (a wholly owned Roche subsidiary since 2014), F. Hoffmann-La Roche, Sanofi-Aventis, and Takeda. Maher is supported by a National Institute for Health Research Clinician Scientist Fellowship (NIHR Ref: CS:-2013-13-017). Dejonckheere is an employee of F. Hoffmann-La Roche. Nathan has received consulting fees from Roche-Genentech and Boehringer Ingelheim. He is also on the speakers bureau for Roche-Genentech and Boehringer Ingelheim and has received research funding from both companies.

All authors contributed equally to study concept and design, data collection and analysis, and manuscript preparation.

References

    1. Ley B, Collard HR, King TE Jr.. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-40. - PubMed
    1. Meltzer EB, Noble PW.. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8. - PMC - PubMed
    1. Strand MJ, Sprunger D, Cosgrove GP, et al. . Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest. 2014;146(3):775-85. - PMC - PubMed
    1. King TE Jr, Albera C, Bradford WZ, et al. .. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014;189(7):825-31. - PubMed
    1. Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L.. Hot off the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax. 2012;67(11):938-40. - PubMed

MeSH terms